2020 ASCO Virtual Scientific Meeting*

Adding pembrolizumab to chemotherapy improves PFS in mTBC with PD-L1 CPS 10 or higher

Addition of veliparib to cisplatin improved median PFS by 47% compared with cisplatin and placebo in gBRCA-negative metastatic TNBC patients with BRCA-like phenotype.

Tucatinib plus trastuzumab/capecitabine demonstrated statistically significant and clinically meaningful improvements in intracranial response rate, CNS-PFS, and OS in patients with brain metastases.

Alpelisib plus fulvestrant demonstrated clinically meaningful efficacy based on the proportion of patients alive without PD at 6 months in this analysis of patients with PIK3CA-mutated HR+/HER2- advanced BC previously treated with CDK4/6i plus AI.

In this pooled analysis of ctDNA from 3 MONALEESA breast cancer studies, multiple potential biomarkers of ribociclib sensitivity and resistance were identified.

Ribociclib plus ET associated with prolonged OS and PFS in patients with HR+/HER2- breast cancer and visceral metastases.

Ribociclib plus letrozole appears safe and effective as first-line endocrine therapy in an expanded patient population with HR+, HER2- advanced breast cancer regardless of menopausal status.

Secondary cytoreductive surgery with complete resection in patients with platinum-sensitive recurrent ovarian cancer and a positive AGO Score leads to substantial improvement in survival outcomes.

Maintenance olaparib increased median OS by more than 1 year vs placebo and was well tolerated over prolonged treatment duration.

Pembrolizumab monotherapy resulted in ORR of 8.5% with median DoR of 10.2 mos and median OS of 18.7 mos in patients with advanced recurrent ovarian cancer.

In this updated analysis, niraparib plus bevacizumab prolonged PFS and time to subsequent therapies over niraparib alone in patients with platinum-sensitive recurrent ovarian cancer.

Individualized dosing of niraparib based on weight and platelet count improves tolerability with no loss of efficacy.

Lenvatinib plus pembrolizumab showed promising efficacy as early-line treatment for patients with advanced endometrial cancer that is not MSI-H or dMMR in this post hoc analysis of KEYNOTE-146.

Addition of early local therapy to systemic therapy for intact primary tumors in patients with de novo MBC was not associated with a survival benefit vs continued systemic therapy alone.